COMP <GO>
YDES vs JNJ // RSI-14 & 200D SMA MOMENTUM
YD Bio Limited (NASDAQ) VS. Johnson & Johnson (NYSE) • 15-METRIC TALLY: YDES 2
— JNJ 8
▲ RSI-14 & 200D SMA MOMENTUM LEADER: JNJ
LAST: $5.87 (-6.53%) • MKT CAP: $415.8M
rsi-technicals
51.7
LAST: $275.20 (+1.54%) • MKT CAP: $662.49B
rsi-technicals
62.1
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (YDES VS. JNJ)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | YDES | JNJ | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 28.10% | 67.90% | -39.80 | JNJ | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -20.00% | 25.50% | -45.50 | JNJ | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | 18.5x | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | -1.93% | 2.97% | -4.90 | JNJ | /fcf-yield <GO> |
| Operating Margin | -60.00% | 34.70% | -94.70 | JNJ | /operating-margins <GO> |
| Net Profit Margin | -60.00% | 28.50% | -88.50 | JNJ | /net-margins <GO> |
| Revenue Growth (YoY) | 16.90% | 6.00% | +10.90 | YDES | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 13.44 | 5.59 | +7.85 | YDES | /balance-sheet <GO> |
| Piotroski F-Score Quality | 4/9 | 8/9 | -4.00 | JNJ | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum ACTIVE | 51.7 | 62.1 | -10.40 | JNJ | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | 1.08 | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | 23.0x | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $415.8M | $662.49B | -$662.08B | JNJ | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | YDES REV | JNJ REV | YDES GROSS % | JNJ GROSS % | YDES FCF | JNJ FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $596.8K | $94.19B | 28.1% | 67.9% | -$8.0M | $19.70B |
| FY 2024 | $510.4K | $88.82B | 30.4% | 69.1% | -$1.3M | $19.84B |
| FY 2023 | $350.1K | $85.16B | — | — | -$55.7K | $18.96B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
YDES // BETA —
JNJ // BETA 1.08